Second Sight Names Scott Dunbar Acting CEO

By
LOS ANGELES—Second Sight Medical Products (NASDAQ: EYES), a leading developer and marketer of implantable visual prosthetics for blind individuals, announced that the company’s board of directors has named Scott Dunbar to replace Matthew Pfeffer as acting chief executive officer. Under Nasdaq rules, an independent director may temporarily be named acting CEO, but such service cannot continue for more than one year. Accordingly, Pfeffer has relinquished the role of acting CEO but will remain on the board as an independent director.

Scott Dunbar, senior patent counsel and compliance officer, has served the company for 19 years.